Labrys Biologics Snags $31M Series A, CEO and Pfizer MAb
By Marie Powers
Staff Writer
Staff Writer
Thursday, January 3, 2013
Labrys Biologics Inc. burst on the biotech scene with a $31 million Series A, a new president and CEO and the acquisition of a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc. to treat chronic migraine.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.